Product Description
Mechanisms of Action: Gene Therapy
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hookipa Biotech
Company Location: NEW YORK NY 10016
Company CEO: Joern Aldag
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for HB-502](https://pryzm-maps.s3.us-west-2.amazonaws.com/9current_maps.png)
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Acquired Immunodeficiency Syndrome|HIV Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
H-500-001 | P1 |
Recruiting |
Acquired Immunodeficiency Syndrome|HIV Infections |
2025-11-01 |